Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 34.90% | -33.26% | 107.00% | 54.82% | 31.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.90% | -33.26% | 107.00% | 54.82% | 31.25% |
| Cost of Revenue | 19.75% | 1.89% | -19.56% | 20.24% | 67.48% |
| Gross Profit | 38.57% | -37.71% | 153.30% | 62.00% | 24.70% |
| SG&A Expenses | 49.07% | 10.95% | 15.70% | 14.78% | -5.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.57% | 7.67% | 11.42% | 14.64% | 6.20% |
| Operating Income | 9.66% | -135.96% | 121.15% | 71.01% | 38.28% |
| Income Before Tax | -40.87% | -172.09% | 95.93% | 63.11% | 33.49% |
| Income Tax Expenses | -60,315.85% | -2.71% | 215.26% | 35.02% | -61.23% |
| Earnings from Continuing Operations | 39.24% | -175.51% | 93.88% | 62.13% | 33.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.24% | -175.51% | 93.88% | 62.13% | 33.55% |
| EBIT | 9.66% | -135.96% | 121.15% | 71.01% | 38.28% |
| EBITDA | 11.59% | -127.70% | 129.36% | 77.96% | 40.95% |
| EPS Basic | 40.90% | -173.53% | 93.98% | 62.74% | 34.79% |
| Normalized Basic EPS | -36.17% | -162.22% | 96.50% | 63.17% | 36.45% |
| EPS Diluted | 40.90% | -175.53% | 93.98% | 62.74% | 35.10% |
| Normalized Diluted EPS | -36.17% | -165.27% | 96.50% | 63.17% | 36.45% |
| Average Basic Shares Outstanding | 2.79% | 2.69% | 1.66% | 1.63% | 1.90% |
| Average Diluted Shares Outstanding | 2.79% | -2.09% | 1.66% | 1.63% | 1.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |